BCG Moreau Vaccine Safety Profile and NK Cells-Double Protection Against Disseminated BCG Infection in Retrospective Study of BCG Vaccination in 52 Polish Children with Severe Combined Immunodeficiency.
BCG Moreau vaccine
NKcells
Primary immunodeficiencies
disseminated BCG infection
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
22
02
2019
accepted:
14
10
2019
pubmed:
22
11
2019
medline:
12
2
2021
entrez:
22
11
2019
Statut:
ppublish
Résumé
The aim of the study was to estimate the rate of adverse reactions to live BCG Moreau vaccine, manufactured by Biomed in Poland, in severe combined immunodeficiency (SCID) patients. The profiles of 52 SCID patients vaccinated at birth with BCG, hospitalized in Children's Memorial Health Institute, Warsaw (CMHI), in the years 1980-2015 were compared with those of 349 BCG-vaccinated SCID patients from other countries analyzed by Beatriz E. Marciano et al. in a retrospective study (Marciano et al. J Allergy Clin Immunol. 2014;133(4):1134-1141). Significantly less disseminated BCG infections (10 out of 52 SCID, 19%) occurred in comparison with Marciano study-119 out of 349, 34% (p = 0.0028), with no death in patients treated with SCID anti-TB drug, except one in lethal condition. In our study, disseminated BCG infection was observed only in SCID with T-B+NK- phenotype and significantly lower NK cell counts (p = 0.0161). NK cells do not influence on the frequency of local BCG reaction. A significantly higher number of hematopoietic stem cells transplantations (HSCT) were performed in CMHI study (p = 0.0001). Anti-TB treatment with at least two medicines was provided. The BCG Moreau vaccine produced in Poland, with well-documented genetic characteristics, seems to be safer than other BCG substrains used in other regions of the world. Importantly, NK cells seem to play a role in protecting SCID patients against disseminated BCG complications, which NK- SCID patients are more prone to. HSCT and TB therapy could be relevant due to the patients' survival and the fact that they protect against BCG infection.
Identifiants
pubmed: 31749033
doi: 10.1007/s10875-019-00709-1
pii: 10.1007/s10875-019-00709-1
pmc: PMC7082382
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-146Références
BCG vaccines: WHO position paper – February 2018. Weekly Epidemiological Record, No 8, 23 February 2018,93,73–96
Recommendations to assure the quality, safety and efficacy of BCG vaccines, WHO Technical Report Series No.979, 2013; 137–185
Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev. 2008;32(5):821–41.
doi: 10.1111/j.1574-6976.2008.00118.x
BCG vaccine. WHO position paper. Weekly Epidemiological Report, No 4, 23 January 2004, 25–40.
Safety update of BCG vaccine. Report of GACVS meeting of 7–8 June 2017, Weekly Epidemiological Report, No 28, 92, 396–398.
Peltola H, Salmi I, Vahvanen V, Ahlqvist J. BCG vaccination as a cause of osteomyelitis and subcutaneous abscess. Arch Dis Child. 1984;59:157–61.
doi: 10.1136/adc.59.2.157
Böttiger M, Romanus V, de Verdier C, Boman G. Osteitis and other complications caused by generalized BCG-itis. Experiences in Sweden. Acta Paediatr Scand. 1982;71(3):471–8.
doi: 10.1111/j.1651-2227.1982.tb09454.x
Kröger L, Brander E, Korppi M, Wasz-Höckert O, Backman A, Kröger H, et al. Osteitis after newborn vaccination with three different Bacillus Calmette-Guerin vaccines: twenty-nine years of experience. Pediatr Infect Dis J. 1994;13:113–6.
Koyama A, Toida I, Nakata S. Osteitis as a complication of BCG vaccination. Kekkaku. 2009;84(3):125–32.
pubmed: 19364044
Olakowski T, Iwanowa O, Mardoń K. Kontrolowane badania szczepionek BCG. Szczepienia noworodków w Warszawie szczepionkami BCG z podszczepu francuskiego. Gruźlica i Choroby Płuc. 1972;40(5):403–9.
pubmed: 5030596
Zapaśnik-Kobierska H, Stopnicka M. Porównanie wyników szczepień BCG szczepionką liofilizowaną sporządzoną ze szczepów BCG różnego pochodzenia. Pediatr Pol. 1956;31(6):627–37.
pubmed: 13378902
Nissen TN, Birk NM, Kjærgaard J, Thøstesen LM, Pihl GT, Hoffmann T, et al. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. Vaccine. 2016;34(22):2477–82.
Szczuka I. Adverse events following immunization with BCG vaccine in Poland 1994–2000. Przegl Epidemiol. 2002;56:205–16.
pubmed: 12371352
Casanova JL, Jounguy E, Lamhamedi S, Jounguy S, Lamhamedi S, Blanche S, et al. Immunological conditions of children with BCG disseminated infection. Lancet. 1995;346(8974):581.
Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, et al. Idiopathic disseminated bacillus Calmette- Guérin infection: a French national retrospective study. Pediatrics. 1996;98(4 Pt 1):774–8.
Stephan JL, Velekova, Le Deist F, Blanche S, Donadieu J, De Saint-Basile G, et al. A retrospective single-center study of clinical presentation and outcome in 117 patients with severe combined immunodeficiency. J Pediatr. 1993;123:564–72.
Picard C, Gaspar HB, Waleed AH, Aziz Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96–128.
Wolska-Kusnierz B, Bernatowska E, Pac M, Pietruch B, Kurenko-Deptuch M, Lange A. Vaccination and post-vaccination adverse events in children hospitalised in the Department of Immunology, Children’s Memorial Health Institute in years 1980-2003. Stand Med. 2003;5(43):1062–8 (in Polish).
Bernatowska E, Wolska-Kuśnierz B, Pac M, Zwolska Z, Casanova JL, Piatosa B, et al. Disseminated bacillus Calmette-Guerin infection and immunodeficiency. Emerg Infect Dis. 2007;13(5):799–801.
Mazzucchelli JT, Bonfim C, Castro GG, et al. Severe combined immunodeficiency in Brazil: management, prognosis, and BCG-associated complications. J Investig Allergol Clin Immunol. 2014;24(3):184–91.
pubmed: 25011356
Ying W, Sun J, Liu D, Hui X, Yu Y, Wang J, et al. Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study. PLoS One. 2014;9(4):e94485. https://doi.org/10.1371/journal.pone.0094485 eCollection 2014.
de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12beta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89:381–402.
doi: 10.1097/MD.0b013e3181fdd832
Dorman SE, Picard C, Lammas D, Heyne K, van Dissel J, Baretto R, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. 2004;364:2113–21.
doi: 10.1016/S0140-6736(04)17552-1
Liberek A, Korzon M, Bernatowska E, Kurenko-Deptuch M, Rydlewska M. Vaccination-related Mycobacterium bovis BCG infection. Emerg Infect Dis. 2006;12(5):860–2.
doi: 10.3201/eid1205.050107
Pac M, Buda P, Bustamante J, Wieteska-Klimczak A, Ziołkowski J, Krasińska M, et al. Not typical disseminated Mycobacterium tuberculosis complex infection in a girl with partial dominant IFN-γ receptor 1 deficiency. Central Eur J Immunol. 2012;37(4):378–81.
doi: 10.5114/ceji.2012.32667
Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64:543–54.
doi: 10.1016/j.jinf.2012.03.012
Sadedhi-Shandestari M, Asarin K, HudiehMaljaei S, Rafeey M, Pezeshki Z, Kousha A, et al. Immunologic aspects of patients with disseminated bacilli Calmette-Guerin disease in north-west of Iran. Ital J Pediatr. 2009;35:42.
doi: 10.1186/1824-7288-35-42
Van den Berg JM, van Koopen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234.
doi: 10.1371/journal.pone.0005234
Fatemeh Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M, Fazlollahi MR, Mansouri SD. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31(5):792–801.
doi: 10.1007/s10875-011-9567-x
Canadien Tuberculosis Standard, Ed. Public Health Agency of Canada, chapter 7. Behr M, Kevin Elwood K. BacilleCalmette – Guerin (BCG) vaccination in Canada, 2014.
Thon V. Necessity of postpone BCG vaccination - lesson from complications and deaths of children with primary immunodeficiencies. Studia pneumologica et phtiseologica, Praha: Trios, 2010, roč. 70, č. 1, s. 30–34.
Wolska-Kuśnierz B, Gregorek H, Chrzanowska K, Piątosa B, Pietrucha B, Heropolitańska-Pliszka E, et al. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options - a retrospective analysis. J Clin Immunol. 2015;35(6):538–49.
Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E Jr, et al. Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138(1):241–248. e3. https://doi.org/10.1016/j.jaci.2015.11.041 .
Nunes-Santos CJ, Rosenzweig SD. Bacille Calmette-Guerin complications in newly described primary immunodeficiency diseases: 2010-2017. Front Immunol. 2018;9:1423–3. https://doi.org/10.3389/fimmu.2018.01423 eCollection 2018.
Marciano BE, et al. BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41.
doi: 10.1016/j.jaci.2014.02.028
Piątosa B, Wolska-Kuśnierz B, Siewiera K, Grzduk H, Gałkowska E, Bernatowska E. Distribution of leukocyte and lymphocyte subsets in peripheral blood. Age related normal values for preliminary evaluation of the immune status in Polish children. Central Eur J Immunol. 2010;35:168–75 https://www.termedia.pl/Clinical-immunology-Distribution-of-leukocyte-and-lymphocyte-subsets-in-peripheral-blood-Age-related-normal-values-for-preliminary-evaluation-of-the-immune-status-in-Polish-children,10,15414,0,1.html .
Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al. BacilleCalmette- Guérin (BCG) vaccine-induced disease in HIV-infected and uninfected children. Clin Infect Dis J. 2006;42:548–58.
doi: 10.1086/499953
Revised BCG vaccination guidelines for infants at risk for HIV infection. Weekly Epidemiological Report, NO. 21, 25 May 2007,193–196.
Use of BCG vaccine in HIV-infected infants. Weekly epidemiological report, NO.5,29 January 2010, 32–33.
Fernandes RC, de Araújo LC, Medina-Acosta E. Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil. Eur J Pediatr. 2009;168(6):691–6.
doi: 10.1007/s00431-008-0822-y
BCG vaccine, Biomed, Lublin, Poland; https://biomedlublin.com/pl/produkty/szczepionka-przeciwgruzlicza-bcg-100/ .
Grzybowska K, Brzezińska S, Augustynowicz-Kopeć E, Polak M, Augustynowicz E, Anna Lutyńska A. PCR-based genomic deletion analysis of RD-regions in the identification of mycobacteria isolated from adverse events following BCG vaccination or TB suspected cases. Pol J Microbiol. 2014;63(3):359–62.
doi: 10.33073/pjm-2014-048
Krysztopa-Grzybowska K, Brzezińska S, Augustynowicz-Kopeć E, Polak M, Augustynowicz E, Lutyńska A. Descendant of daughter Brazilian BCG Moreau substrain in Poland. Vaccine. 2012;30:5512–8.
doi: 10.1016/j.vaccine.2012.06.056
Krysztopa-Grzybowska K, Lutyńska A. Microevolution of BCG substrains. Postepy Hig Med Dosw (Online). 2016;70(0):1259–66 https://www.ncbi.nlm.nih.gov/pubmed/28026828 .
MacGurin JA. CoxJS. A genetic screen for Mycobacterium tuberculosis mutations defective for phagosome maturation arrest identifies component of the ESX-1 secretion. Infect Immun. 2007;75(6):2668–78.
doi: 10.1128/IAI.01872-06
Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol. 2014;155(2):213–9.
Portevin D, Young D. Natural killer cell cytokine response to M. bovis BCG Is associated with inhibited proliferation, increased apoptosis and ultimate depletion of NKp44(+)CD56(bright) cells. PLoS One. 2013;8(7):e68864. https://doi.org/10.1371/journal.pone.0068864 .
doi: 10.1371/journal.pone.0068864
pubmed: 23874793
pmcid: 3715299
García-Cuesta EM, Esteso G, Ashiru O, López-Cobo S, Álvarez-Maestro M, Linares A, et al. Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes. Oncoimmunology. 2017;6(4):e1293212. https://doi.org/10.1080/2162402X.2017.1293212 eCollection 2017.
Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, et al. Bacillus Calmette-Guérin (BCG) revaccination of adults with latent Mycobacterium tuberculosis infection induces long-lived bcg-reactive NK cell responses. J Immunol. 2016;197(4):1100–10.
IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133(4):1124–33.
Sharapova SO, Skomska-Pawliszak M, Rodina Y, Wolska-Kunierz B, Dbrowska-Leonik N, Pashchenko O, et al. The clinical and genetic spectrum of RAG deficiency including a c. 256_257delAA founder variant in Slavic countries. J Clin Immunol. 2019;39(2):S131–2.
Feinberg J, Fieschi C, Doffinger R, Feinberg M, Leclerc T, Boisson-Dupuis S. Bacillus Calmette Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur J Immunol. 2004;34(11):3276–84. https://doi.org/10.1002/eji.200425221 .
doi: 10.1002/eji.200425221
pubmed: 15384045